SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cell Therapeutics (CTIC)
CTIC 9.0900.0%Jun 26 5:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: soozathelooza who wrote (22)3/26/1998 6:48:00 PM
From: WHL   of 946
 
Here's CTIC's new lead drug. It's already well down the road.
From a previous post:
"I think people are missing the major potential drug in CT-2584. I read from New Scientist ( newscientist.com ) in the 29NOV, 1997 issue that this drug bypasses the usual multidrug resistant mechanism(MDM) where the survivor cells learn to activate cellular pumps that pump out toxic materials at 100 times the rate of normal cells." The net result of bypassing MDM is that the tumor is unable to pump out the toxic materials targeting its destruction.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News